Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

A Study of SC Administration of Trastuzumab (Herceptin) by SID at Home in HER2-Positive EBC Participants

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Trastuzumab

First Posted Date: 2014-01-20

Last Posted Date: 2019-08-22

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 128

Registration Number: NCT02040935

Locations: 🇳🇱
Haga Ziekenhuis, Den Haag, Netherlands
🇳🇱
Tergooiziekenhuizen, loc. Hilversum, Hilversum, Netherlands
🇳🇱
Zuyderland ziekenhuis locatie Geleen, Sittard-Geleen, Netherlands

and more 14 locations

The Pharmacokinetics and Safety of Onartuzumab (MetMAb) in Chinese Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: 4 mg/kg Onartuzumab (MetMAb)
Drug: 15 mg/kg Onartuzumab (MetMAb)
Drug: 30 mg/kg Onartuzumab (MetMAb)

First Posted Date: 2014-01-09

Last Posted Date: 2017-03-14

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 30

Registration Number: NCT02031731

Locations: 🇨🇳
Sun Yet-sen University Cancer Center, Guangzhou, China
🇨🇳
the First Hospital of Jilin University, Changchun, China
🇨🇳
Beijing Cancer Hospital, Beijing, China

A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: erlotinib [Tarceva]
Drug: Onartuzumab [MetMAb]
Drug: Placebo

First Posted Date: 2014-01-09

Last Posted Date: 2017-03-14

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 530

Registration Number: NCT02031744

Locations: 🇨🇳
Southwest Hospital , Third Military Medical University, Chongqing, China
🇨🇳
Harbin Medical University Cancer Hospital, Harbin, China
🇨🇳
Jilin Cancer Hospital, Changchun, China

and more 5 locations

TOSCARA Study: A Study of Subcutaneous Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis Naïve to RoActemra/Actemra Treatment

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: tocilizumab

First Posted Date: 2014-01-09

Last Posted Date: 2017-08-01

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 57

Registration Number: NCT02031471

A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Atezolizumab

First Posted Date: 2014-01-09

Last Posted Date: 2020-01-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 667

Registration Number: NCT02031458

Locations: 🇺🇸
Angeles Clinic & Rsch Inst, Los Angeles, California, United States
🇺🇸
Emory Uni - Winship Cancer Center; Hematology/Oncology, Atlanta, Georgia, United States
🇺🇸
The Cleveland Clinic Foundation, Cleveland, Ohio, United States

and more 107 locations

Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

Phase 3

Completed

Conditions: Neuromyelitis Optica (NMO)
NMO Spectrum Disorder (NMOSD)

Interventions: Drug: Placebo
Drug: Satralizumab
Drug: Baseline Treatment

First Posted Date: 2014-01-07

Last Posted Date: 2023-04-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 85

Registration Number: NCT02028884

Locations: 🇫🇷
Hopital de Hautepierre CHRU de Strasbourg, Strasbourg, France
🇩🇪
NeuroCure Clinical Research Center (NCRC), Berlin, Germany
🇵🇱
M.A. - LEK A. M. Maciejowscy SC. Centrum Terapii SM, Katowice, Poland

and more 37 locations

A Study of RG1662 in Adults and Adolescents With Down Syndrome (CLEMATIS)

Phase 2

Completed

Conditions: Down Syndrome

Interventions: Drug: Placebo
Drug: RG1662

First Posted Date: 2013-12-31

Last Posted Date: 2017-10-25

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 173

Registration Number: NCT02024789

Locations: 🇮🇹
Policlinico Universitario "Agostino Gemelli";Dip. Tutela Salute Donna Bambino Adolescente, Roma, Lazio, Italy
🇲🇽
Clínica Para la Atención del Neurodesarrollo, Aguascalientes, Mexico
🇲🇽
Hospital Universitario Dr. Jose Eleuterio Gonzalez; Pediatria, Monterrey, Mexico

and more 34 locations

A Study Investigating the Effect of Food and Esomeprazole on the Single Oral Dose Pharmacokinetics of Alectinib (RO5424802) in Healthy Volunteers.

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Alectinib
Other: High Fat and Calorie Meal
Drug: Esomeprazole
Other: Standard Meal

First Posted Date: 2013-12-30

Last Posted Date: 2016-10-07

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 42

Registration Number: NCT02023125

A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone

Phase 1

Completed

Conditions: Schizophrenia

Interventions: Other: Placebo
Drug: RO5545965
Drug: risperidone

First Posted Date: 2013-12-24

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 32

Registration Number: NCT02019329

A Study Exmining the Effect of Multiple Doses of Bitopertin on the Single Dose Pharmacokinetics of Midazolam in Healthy Volunteers.

Phase 1

Withdrawn

Conditions: Healthy Volunteer

Interventions: Drug: Midazolam
Drug: bitopertin

First Posted Date: 2013-12-24

Last Posted Date: 2017-10-25

Lead Sponsor: Hoffmann-La Roche

Registration Number: NCT02019290

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy